Delayed profound thrombocytopenia presenting 7 days after use of abciximab (ReoPro).
A case of a 65-year-old woman presenting with delayed profound thrombocytopenia 7 days after the use of abciximab (ReoPro) in the setting of percutaneous coronary intervention is described. The patient had normal platelet counts for the first 24 hours after the use of abciximab (ReoPro). She presented with petechiae and profound thrombocytopenia 1 week later. The patient was treated successfully with a platelet transfusion and recovered uneventfully. Profound thrombocytopenia occurs acutely within the first few hours after abciximab (ReoPro) use, so this case was unique in that the profound thrombocytopenia presented 1 week after use of abciximab (ReoPro).
Sharma
Sanjiv
S
Central Cardiology Medical Clinic and Bakersfield Heart Hospital, 2110 Truxtun Avenue, Bakersfield, CA 93301, USA.
Bhambi
Brijesh
B
Nyitray
William
W
Sharma
Geetanjali
G
Shambaugh
Shawn
S
Antonescu
Adrian
A
Shukla
Pankaj
P
Denny
Eileen
E
D000077284:Abciximab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D006348:Cardiac Surgical Procedures; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects* / Q000627:therapeutic use; D017713:Platelet Transfusion; D011693:Purpura / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced*; D013997:Time Factors
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D000077284:Abciximab